Affordable Access

deepdyve-link
Publisher Website

The In Vivo Effects of the CB1-Positive Allosteric Modulator GAT229 on Intraocular Pressure in Ocular Normotensive and Hypertensive Mice.

Authors
  • Cairns, Elizabeth A1
  • Szczesniak, Anna-Maria1
  • Straiker, Alex J2
  • Kulkarni, Pushkar M3
  • Pertwee, Roger G4
  • Thakur, Ganesh A3
  • Baldridge, William H5, 6
  • Kelly, Melanie E M1, 6
  • 1 1 Department of Pharmacology, Dalhousie University , Halifax, Nova Scotia, Canada . , (Canada)
  • 2 2 Department of Psychological and Brain Sciences, Indiana University , Bloomington, Indiana. , (India)
  • 3 3 Department of Pharmaceutical Sciences School of Pharmacy, Bouvé College of Health Sciences, Northeastern University , Boston, Massachusetts.
  • 4 4 School of Medicine, Medical Sciences, and Nutrition, Institute of Medical Sciences, University of Aberdeen , Aberdeen, Scotland.
  • 5 5 Department of Medical Neuroscience, Dalhousie University , Halifax, Nova Scotia, Canada . , (Canada)
  • 6 6 Department of Ophthalmology and Visual Sciences, Dalhousie University , Halifax, Nova Scotia, Canada . , (Canada)
Type
Published Article
Journal
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
Publication Date
Oct 01, 2017
Volume
33
Issue
8
Pages
582–590
Identifiers
DOI: 10.1089/jop.2017.0037
PMID: 28719234
Source
Medline
Keywords
License
Unknown

Abstract

The CB1 PAM GAT229 reduces IOP in ocular hypertensive mice and enhanced CB1-mediated IOP reduction when combined with subthreshold CB1 orthosteric ligands in normotensive mice. Administration of CB1 PAMs may provide a novel approach to reduce IOP with fewer of the disadvantages associated with orthosteric CB1 activation.

Report this publication

Statistics

Seen <100 times